Acrux Limited Company Profile (ASX:ACR)

About Acrux Limited (ASX:ACR)

Acrux Limited logoAcrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.

Industry, Sector and Symbol: Average Prices:
  • 50 Day Moving Avg: A$0.25
  • 200 Day Moving Avg: A$0.28
P/E:
  • Trailing P/E Ratio: 5.34
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 44.12%
  • Return on Equity: 26.73%
  • Return on Assets: 22.55%
 
Frequently Asked Questions for Acrux Limited (ASX:ACR)

What is Acrux Limited's stock symbol?

Acrux Limited trades on the ASX under the ticker symbol "ACR."

Who are some of Acrux Limited's key competitors?

Who are Acrux Limited's key executives?

Acrux Limited's management team includes the folowing people:

  • Michael Kotsanis, Chief Executive Officer, Managing Director, Executive Director
  • Tim Bateman, Chief Financial Officer, Company Secretary
  • Nina Webster, Commercial Director
  • Felicia Colagrande, Product Development and Technical Affairs Director
  • C O'Sullivan, Portfolio Director
  • Ross Dobinson, Non-Executive Chairman of the Board
  • Geoffrey E.D. Brooke M.D., Non-Executive Director
  • Simon Green, Non-Executive Director
  • Timothy Charles Oldham, Non-Executive Director


MarketBeat Community Rating for Acrux Limited (ASX ACR)
Community Ranking:  1.8 out of 5 ()
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  28
MarketBeat's community ratings are surveys of what our community members think about Acrux Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acrux Limited (ASX:ACR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Acrux Limited (ASX:ACR)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Acrux Limited (ASX:ACR)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Acrux Limited (ASX:ACR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Acrux Limited (ASX:ACR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acrux Limited (ASX:ACR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Acrux Limited (ASX:ACR)
Latest Headlines for Acrux Limited (ASX:ACR)
Source:
DateHeadline
fool.com logoAcrux Limited share price jumps on strong sales data - Motley Fool Australia
www.fool.com.au - July 26 at 3:25 PM
fool.com logoWhy I think it's time to sell Sirtex Medical Limited shares - Motley Fool Australia
www.fool.com.au - May 22 at 5:46 AM
businesswire.com logoMitsui & Co., Ltd. UK Regulatory Announcement: Final Results - Replacement - Business Wire (press release)
www.businesswire.com - May 11 at 8:32 PM
businesswire.com logoMitsui & Co., Ltd. UK Regulatory Announcement: Final Results - Business Wire (press release)
www.businesswire.com - May 9 at 9:29 AM
reuters.com logoBRIEF-Acrux says U.S. Patent and Trademark Office institutes IPR proceeding against a U.S. Patent
www.reuters.com - May 2 at 5:52 AM
fool.com logoWhy the Acrux Limited share price has cratered in 2017 - Motley Fool Australia
www.fool.com.au - March 10 at 3:18 PM
biz.yahoo.com logoInterim 2017 Acrux Ltd Earnings Release - Time Not Supplied
biz.yahoo.com - February 17 at 6:45 PM
reuters.com logoBRIEF-Acrux Ltd reports quarterly global Axiron sales of US$39.9 mln - Reuters
www.reuters.com - January 31 at 8:22 PM
fool.com logoWhat I think you should do with your Sirtex Medical Limited shares
www.fool.com.au - December 21 at 10:55 AM
fool.com logoWhat I think you should do with your Sirtex Medical Limited shares - Motley Fool Australia
www.fool.com.au - December 20 at 8:15 PM
fool.com logoDown 57%: Is Acrux Limited a bargain buy?
www.fool.com.au - November 25 at 8:27 AM
reuters.com logoBRIEF-Acrux Ltd files inter partes review petition against Key Jublia Patent
www.reuters.com - November 3 at 12:59 PM
reuters.com logoBRIEF-Acrux Ltd appoints Tim Bateman as Chief Financial Officer
www.reuters.com - October 11 at 3:18 PM
biz.yahoo.com logoPreliminary 2016 Acrux Ltd Earnings Release - Time Not Supplied
biz.yahoo.com - August 25 at 8:05 AM
seekingalpha.com logoPatent Dispute Off The Rails For Eli Lilly And Acrux
seekingalpha.com - August 23 at 3:15 PM
fool.com logoAcrux Limited shares crater 37% on shock court ruling
www.fool.com.au - August 23 at 3:15 PM

Social

Social activity is not available for this stock.
This page was last updated on 7/28/2017 by MarketBeat.com Staff